← Leaderboards
Anita L Sabichi
University Of Texas Md Anderson Can Ctr
$800,984
Attributed
$800,984
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $0 · FY2006–24$1$1$1$0$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$800,984 · 2
VA$0 · 1
By mechanism
N01$800,984 · 2
I01$0 · 1
Top collaborators
- Farrah Kheradmand1 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Funda Meric-Bernstam$12,297,463
- Patrick M Dougherty$11,432,670
- Elizabeth A Grimm$11,275,665
- Xifeng Wu$28,679,533
- Jeffrey Nicholas Myers$13,165,599
Others in their field
Top investigators on “Adjuvant”
- Lawrence Corey · Fred Hutchinson Cancer Center$377,142,999
- Norman Wolmark · Nsabp Foundation, Inc.$267,141,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$167,183,168
- David Heimbrook · Leidos Biomedical Research, Inc.$151,668,128
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$131,206,481
- Peter B. Gilbert · Fred Hutchinson Cancer Center$117,668,001
Research focus
AdjuvantAdjuvant TherapyAftercareAgonistAntibodiesAntigen-Antibody ComplexAntigen-Presenting CellsAntigensAntitumor ResponseBindingBiologicalCancer PatientCancer TherapyCancer TypeCandidate IdentificationChemotherapyClinical DataClinical TrialsCohortCombined Modality TherapyDepositionDistant MetastasisDoseAdaptive Immune Response
Grant awards (3)
Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC$0
I01 · FY2024 · VA
PHASE II CLINICAL TRIAL OF CELECOXIB OR (NSAID) IN BLADDER DYSPLASIA --261085186$0
N01 · FY2006 · CA · contact PI
PHASE II CLINICAL TRIAL OF CELECOXIB OR (NSAID) IN BLADD$800,984
N01 · FY2000 · CN